Immutep Receives Regulatory Clearance For Phase I Study Of First-In-Class LAG-3 Agonist Antibody Designed To Treat Autoimmune Diseases
Immutep Receives Regulatory Clearance For Phase I Study Of First-In-Class LAG-3 Agonist Antibody Designed To Treat Autoimmune Diseases
- Study expected to enrol first participants during Q3 CY2024
- 該研究預計將在 CY2024 第三季度招收第一批參與者
SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearance from the ethics and competent authority in the Netherlands to initiate the first-in-human Phase I study of IMP761.
澳大利亞悉尼，2024 年 7 月 17 日（GLOBE NEWSWIRE）——開發針對癌症和自身免疫性疾病的新型 LAG-3 免疫療法的臨床階段生物技術公司Immutep Limited（（澳大利亞證券交易所股票代碼：iMM，納斯達克股票代碼：IMMP）（“Immutep” 或 “公司”）今天宣佈，它已獲得荷蘭倫理和主管當局的監管許可，啓動首次人體 I 期研究 IMP761 的。
IMP761 is the world's first therapeutic LAG-3 agonist antibody and as such is uniquely positioned in the treatment landscape for autoimmune diseases. The immune checkpoint LAG-3 has been identified as a promising target for agonist immunotherapy to treat rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis, among other autoimmune diseases.1,2,3 IMP761 is designed to restore balance to the immune system by enhancing the "brake" function of LAG-3 to silence unregulated self-antigen-specific memory T cells. These T cells accumulate at disease sites and are the underlying cause of many autoimmune diseases.
IMP761 是世界上第一個治療性 LAG-3 激動劑抗體，因此在自身免疫性疾病的治療領域具有獨特的地位。免疫檢查點 LAG-3 已被確定爲治療類風溼關節炎、1 型糖尿病和多發性硬化症以及其他自身免疫性疾病的激動劑免疫療法的有前景靶標。1,2,3 IMP761 旨在通過增強 LAG-3 的 “制動” 功能來抑制不受調節的自我抗原特異性記憶 T 細胞，從而恢復免疫系統的平衡。這些 T 細胞積聚在疾病部位，是許多自身免疫性疾病的根本原因。